GPX4 and triple-negative breast carcinoma: Nanocatalytic activity leads to simultaneous inhibition of GPX4/GSH and FSP1/coq10h2 pathways and synergizes with the GPX4 inactivation function of RSL3 to cause significant ferroptosis damage and thus inhibit malignant progression of triple-negative breast cancer (112).